» Articles » PMID: 39456495

Vitamin C in the Management of Thyroid Cancer: A Highway to New Treatment?

Overview
Date 2024 Oct 26
PMID 39456495
Authors
Affiliations
Soon will be listed here.
Abstract

Thyroid cancer (TC) is the most common endocrine malignancy, with an increased global incidence in recent decades, despite a substantially unchanged survival. While TC has an excellent overall prognosis, some types of TC are associated with worse patient outcomes, depending on the genetic setting. Furthermore, oxidative stress is related to more aggressive features of TC. Vitamin C, an essential nutrient provided with food or as a dietary supplement, is a well-known antioxidant and a scavenger of reactive oxygen species; however, at high doses, it can induce pro-oxidant effects, acting through multiple biological mechanisms that play a crucial role in killing cancer cells. Although experimental data and, less consistently, clinical studies, suggest the possibility of antineoplastic effects of vitamin C at pharmacological doses, the antitumor efficacy of this nutrient in TC remains at least partly unexplored. Therefore, this review discusses the current state of knowledge on the role of vitamin C, alone or in combination with other conventional therapies, in the management of TC, the mechanisms underlying this association, and the perspectives that may emerge in TC treatment strategies, and, also, in light of the development of novel functional foods useful to this extent, by implementing novel sensory analysis strategies.

Citing Articles

Free radicals and their impact on health and antioxidant defenses: a review.

Chandimali N, Bak S, Park E, Lim H, Won Y, Kim E Cell Death Discov. 2025; 11(1):19.

PMID: 39856066 PMC: 11760946. DOI: 10.1038/s41420-024-02278-8.

References
1.
Choi Y, Kim H, Kim Y, Park S, Chwae Y, Lee J . B-RafV600E inhibits sodium iodide symporter expression via regulation of DNA methyltransferase 1. Exp Mol Med. 2014; 46:e120. PMC: 4261912. DOI: 10.1038/emm.2014.68. View

2.
Tang P, Dang H, Huang J, Xu T, Yuan P, Hu J . NADPH oxidase NOX4 is a glycolytic regulator through mROS-HIF1α axis in thyroid carcinomas. Sci Rep. 2018; 8(1):15897. PMC: 6203707. DOI: 10.1038/s41598-018-34154-8. View

3.
Carvalho D, Dupuy C . Role of the NADPH Oxidases DUOX and NOX4 in Thyroid Oxidative Stress. Eur Thyroid J. 2014; 2(3):160-7. PMC: 4017742. DOI: 10.1159/000354745. View

4.
Martinez-Cadenas C, Bosch N, Penas L, Flores-Couce E, Ochoa E, Munarriz J . Malignant melanoma arising from a perianal fistula and harbouring a BRAF gene mutation: a case report. BMC Cancer. 2011; 11:343. PMC: 3199871. DOI: 10.1186/1471-2407-11-343. View

5.
Guerra A, Zeppa P, Bifulco M, Vitale M . Concomitant BRAF(V600E) mutation and RET/PTC rearrangement is a frequent occurrence in papillary thyroid carcinoma. Thyroid. 2013; 24(2):254-9. DOI: 10.1089/thy.2013.0235. View